Sera Prognostics Q3 PreTRM revenue jumps 163% on test volume growth
Overview
U.S. pregnancy diagnostics firm's Q3 PreTRM test revenue rose 163% yr/yr
PreTRM test volumes increased 54% sequentially and nearly five-fold from Q1 2026
Operating expenses declined 11% sequentially after cost reduction initiatives in June 2026
Outlook
Company expects increased test volume in fiscal year 2027
Sera Prognostics is in discussions for a multi-state, multi-thousand-patient pilot with a large insurer, planned for fiscal 2027
Company has started CE Mark submission for PreTRM Global in Europe
Result Drivers
TEST VOLUME GROWTH - PreTRM test volumes rose 54% sequentially and nearly five-fold from Q1 2026, driven by PRIME study publication and commercial team expansion
LOWER AVERAGE SELLING PRICES - Revenue growth was limited by a higher mix of low or non-reimbursed tests, which reduced average selling prices
MEDICAID COVERAGE EXPANSION - Florida and Illinois added PreTRM to Medicaid coverage, expanding access to approximately 7 mln covered Medicaid lives
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 PreTRM Test Revenue | $42,000 | ||
Q3 Net Loss | $8.05 mln | ||
Q3 Income from Operations | -$8.89 mln | ||
Q3 Loss Per Basic Share | $0.16 | ||
Q3 Operating Expenses | $8.93 mln |
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the business support services peer group is "buy."
Wall Street's median 12-month price target for Sera Prognostics, Inc. is $5.50, about 185% above its November 3 closing price of $1.93
Reuters Recommended Reads
Nov 3 - Pfizer Q3 revenue beats estimates on new launches; raises guidance
Nov 3 - Amgen Q3 revenue beats expectations on higher volumes
Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)